Azintamide is a potent choleretic agent used primarily in combination formulations to treat digestive disorders caused by insufficient bile secretion or deficiency of digestive enzymes. These conditions include chronic pancreatitis, cholelithiasis, cholecystitis, post-cholecystectomy syndrome, T-tube drainage after surgery, liver cirrhosis with impaired hepatic function, chronic atrophic gastritis, age-related digestive dysfunction, and adverse gastrointestinal effects of radiotherapy and chemotherapy. Symptoms alleviated by this formulation include loss of appetite, abdominal distension, abdominal pain, belching, nausea, epigastric discomfort, diarrhea, and constipation.
Additionally, azintamide reduces the incidence of cholelithiasis by inhibiting cholesterol synthesis, lowering cholesterol concentration in bile, and modulating gallbladder contractility. Its mechanism of action may involve: (1) slowing hepatic cholesterol synthesis and secretion by affecting liver lipid metabolism, thereby altering bile composition and physicochemical properties; (2) influencing the expression of nucleating factors in bile; and (3) modulating gallbladder motility.